The recent flurry of drug approvals has markedly altered the treatment landscape in AML providing patients with new opportunities. The space is getting more exciting as improved genetic testing, combinations of targeted therapies, and the advancement of immunotherapies will finally provide physicians options to advance beyond Walkman-era treatments.
Interest in the EGFR Lung cancer space initially started with the isolation of Epidermal growth factor (EGF) gene by Stanley Cohen in 1962 as a protein extracted from the mouse submaxillary gland that accelerated incisor eruption. Therefore, it was originally termed ‘tooth-lid factor’, but was later renamed EGF because it stimulated the proliferation of epithelial cells.
Since then substantial progress has been made against lung cancer over the last two decades. Research has also powered the emergence of new targeted treatments which are helping patients live a longer and higher quality life after a lung cancer diagnosis. This infographic allows the reader to dwell deeper and look closely into the history of discovery, evolution and advancements pertaining to EGFR lung cancer space.
Cancer immunotherapy has provided substantial clinical benefit in a significant number of patients with advanced disease. However, the need for more precise immunotherapies and predictive biomarkers remains pressing. This infographics contains a timeline on immunotherapy related biomarkers developed so far.
Research and development within the cancer field is continuously evolving and progressing. This infographic highlights the biggest milestones within the field of cancer research spanning 170 years —from the advent of general anesthesia opening the door for cancer surgery in the mid-1800s to the first gene therapy for cancer approved by the Food and Drug Administration in 2017.